Minerva Neurosciences Inc
Change company Symbol lookup
Select an option...
NERV Minerva Neurosciences Inc
DIS Walt Disney Co
BAC Bank of America Corp
GOOD Gladstone Commercial Corp
ADTN ADTRAN Inc
ALRM Alarm.com Holdings Inc
NLOK NortonLifeLock Inc
PROSY Prosus NV
IMBBY Imperial Brands PLC
VNTR Venator Materials PLC
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Price
Delayed
$3.16
Day's Change
0.06 (1.94%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.22
Day's Low
3.09
Volume
(Light)

Today's volume of 152,957 shares is on pace to be much lighter than NERV's 10-day average volume of 469,073 shares.

152,957
  • Prev Close
    3.10
  • Today's Open
    3.20
  • Day's Range
    3.09-3.22
  • Avg Vol (10-day)
    469.1K
  • Last (time)
    2:49p ET 03/01/21
  • Last (size)
    100
  • 52-Wk Range
    1.81 - 15.22
    LowHigh
  • (05/26/20 - 05/29/20)
    74.59%
  • 154.5%
  • Market Cap
    134.9M
  • Shares Outstanding
    42.7M
  • -0.54
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 1.3
  • 67.12
  • (% of float 02/15/21)
    5.24

Latest News

March 01, 2021
8:30 am ET
Globe Newswire
February 16, 2021
8:15 pm ET
Globe Newswire
February 08, 2021
2:30 pm ET
Accesswire
12:31 pm ET
Accesswire
11:30 am ET
PR Newswire
11:15 am ET
Newsfile
9:44 am ET
Newsfile
6:20 am ET
Accesswire
February 07, 2021
1:13 pm ET
Newsfile
10:31 am ET
Accesswire
February 06, 2021
1:11 pm ET
Newsfile
10:00 am ET
Globe Newswire
February 05, 2021
9:15 pm ET
PR Newswire
8:59 pm ET
BusinessWire
4:50 pm ET
Accesswire
1:00 pm ET
Accesswire
11:52 am ET
Accesswire
11:02 am ET
Newsfile
10:38 am ET
Accesswire
9:40 am ET
Newsfile
February 04, 2021
2:01 pm ET
Newsfile
12:29 pm ET
Newsfile
10:59 am ET
BusinessWire
6:25 am ET
Accesswire
February 03, 2021
8:59 pm ET
Globe Newswire
5:30 pm ET
BusinessWire
4:22 pm ET
Globe Newswire
3:14 pm ET
Globe Newswire
2:30 pm ET
Accesswire
12:33 pm ET
Newsfile
6:09 am ET
Newsfile
February 02, 2021
11:28 pm ET
Newsfile
1:41 pm ET
Accesswire
12:05 pm ET
Accesswire
9:06 am ET
Accesswire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.